Paradigm BioCapital focuses its investments on transformative therapeutics within the biotechnology and life sciences sectors. The firm employs a strategy driven by rigorous fundamental research, including scientific and medical due diligence, to identify high-conviction long and short positions, prioritizing capital preservation and attractive risk-adjusted returns.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (50% of deals).
Portfolio
2
Fund Size
$3.1B
Top Stage
Series C
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
2 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
Top Co-Investors
Braidwell LP2 shared
BVF Partners LP2 shared
Deep Track Capital2 shared
Logos Capital2 shared
General Catalyst1 shared
Novo Holdings1 shared
RA Capital Management1 shared
SR One1 shared
Eli Lilly and Company1 shared
Catalio Capital Management1 shared
Janus Henderson Investors1 shared
Marshall Wace1 shared
Samsara BioCapital1 shared
Woodline Partners1 shared
Wellington Management1 shared
Fairmount1 shared
RTW Investments1 shared
Blackstone Inc.1 shared
Frazier Life Sciences1 shared
Last updated: 4 May 2026